UMIN-CTR Clinical Trial

UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials


Recruitment status Completed
Unique ID issued by UMIN UMIN000001857
Receipt No. R000002236
Scientific Title A phase I study of cancer vaccine with NY-ESO-1 overlapping peptides in patients with advanced cancers expressing NY-ESO-1 antigen
Date of disclosure of the study information 2009/04/10
Last modified on 2016/10/12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments

Basic information
Public title A phase I study of cancer vaccine with NY-ESO-1 overlapping peptides in patients with advanced cancers expressing NY-ESO-1 antigen
Acronym Cancer vaccine with NY-ESO-1 overlapping peptides
Scientific Title A phase I study of cancer vaccine with NY-ESO-1 overlapping peptides in patients with advanced cancers expressing NY-ESO-1 antigen
Scientific Title:Acronym Cancer vaccine with NY-ESO-1 overlapping peptides

Condition advanced esophageal cancer, stomach cancer, non-small cell lung cancer (NSCLC), malignant melanoma, bladder cancer.
Classification by specialty
Gastroenterology Pneumology Gastrointestinal surgery
Hepato-biliary-pancreatic surgery Chest surgery Dermatology
Classification by malignancy Malignancy
Genomic information NO

Narrative objectives1 We identified the highly antigenic region in NY-ESO-1 molecule recognized by CD4 and CD8 T cells using an IFN-gamma secretion assay and individual overlapping peptides spanning the entire NY-ESO-1 protein for stimulation. Regions II(73-114) and III(121-144) were frequently recognized by either CD4 or CD8 T cells irrespective of patients' HLA type. Moreover, the most dominant peptide region (91-108) eliciting antibody response was also included in the region II. Based on these findings, we will investigate the safety and immunogenicity of four overlapping long peptides (NY-ESO-1 peptide #1(79-108); peptide #2(100-129); peptide #3(121-150); peptide #4(142-173))for cancer vaccine.
Basic objectives2 Safety
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Phase I

Primary outcomes Toxicities and adverse events defined by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Scale.
Key secondary outcomes NY-ESO-1 specific immunity will be assessed using blood. NY-ESO-1 reactive antibodies measured by ELISA and cellular immunity by NY-ESO-1 specific CD4 and CD8 T cells by cytokine secretion as determined by FACS analysis will be assayed. Tumor response will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST). Disease status will be assessed at baseline and 2 weeks after the sixth vaccination in patients with evaluable (measurable and non-measurable) disease.

Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Dynamic allocation
Institution consideration

No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine Vaccine
Interventions/Control_1 NY-ESO-1 OLP (4 peptides total 1 mg)+Montanide ISA-51 (1.0 mL)+ K-432 (Picibanil) (0.2 KE)
Every 2 weeks x 6 times

Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >=
Gender Male and Female
Key inclusion criteria 1.Histological diagnosis of any type of cancers expressing NY-ESO-1 antigen.
2.Advanced cancer patient.
3.Performance status of 0-2.
4.Age 20-80 years.
5.At least 4 weeks since radiotherapy, biological therapy, chemotherapy or surgery prior to first dosing of study agent.
6.Life expectancy > 3 months.
7.Laboratory values within the following limits:
WBC > 3000/mm3
Neutrophil count > 1500/mm3
Hemoglobin> 8.0 g/dL
Platelet count > 80,000/mm3
Serum bilirubin < 2.0 mg/dl
AST,ALT < 150 IU/l
Serum creatmine < 2.0 mg/dL
8.Tumor with NY-ESO-1 expression
9.Able and willing to give witnessed, written informed consent for participation in the trial
10.Evaluable tumor penicillin allergy
Key exclusion criteria 1.Clinically significant heart disease (i.e., NYHA class 3 congestive heart failure; myocardial infarction within the past six months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias).
2.Other serious illnesses, e.g., serious infections requiring antibiotics, bleeding disorders.
3.Previous bone marrow or stem cell transplant.
4.History of immunodeficiency disease or autoimmune disease except vitiligo.
5.Metastatic disease to the central nervous system, unless treated and stable.
6.Other malignancy within 3 years prior to entry into the study, except for treated early-stage melanoma or non-melanoma skin cancer, or cervical carcinoma in situ.
7.Known HIV, positivity.
8.Concomitant treatment with steroids. Topical or inhalational steroids are permitted. (See also Section 6.7 for restrictions/recommendations on 'Ancillary Therapy'.)
9.Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study agent.
10.Pregnancy or lactation.
11.Women of childbearing potential not using a medically acceptable means of contraception.
12.Psychiatric or addictive disorders that may compromise the ability to give informed consent.
13.Lack of availability of the patient for immunological and clinical follow-up assessment.
Target sample size 9

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Eiichi Nakayama
Organization Okayama University Graduate School of
Medicine, Dentistry and Pharmaceutical Sciences
Division name Department of Immunology
Zip code
Address 2-5-1 Shikata-cho, Okayama 700-8558, Japan
TEL 086-235-7187

Public contact
Name of contact person
1st name
Middle name
Last name Hisashi Wada
Organization Osaka University Graduate School of Medicine
Division name Department of Surgery
Zip code
Address 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
TEL 06-6879-3251
Homepage URL

Institute Department of Immunology
Okayama University Graduate School of
Medicine, Dentistry and Pharmaceutical Sciences

Funding Source
Organization Ludwig Institute for Cancer Research, NY, USA
Category of Funding Organization Outside Japan
Nationality of Funding Organization USA

Other related organizations
Co-sponsor Department of Surgery and Clinical Oncology, Osaka University Graduate School of Medicine

Department of Immunotherapeutics
Graduate School of Medicine
The University of Tokyo
Name of secondary funder(s) The Ministry of Education, Culture, Sports, Science and Technology of Japan.

IRB Contact (For public release)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2

Institutions 川崎医大・呼吸器内科

Other administrative information
Date of disclosure of the study information
2009 Year 04 Month 10 Day

Related information
URL releasing protocol
Publication of results Published

URL related to results and publications
Number of participants that the trial has enrolled
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Recruitment status Completed
Date of protocol fixation
2009 Year 01 Month 01 Day
Date of IRB
Anticipated trial start date
2009 Year 03 Month 01 Day
Last follow-up date
2014 Year 03 Month 01 Day
Date of closure to data entry
2014 Year 09 Month 01 Day
Date trial data considered complete
2014 Year 09 Month 01 Day
Date analysis concluded
2014 Year 12 Month 01 Day

Other related information

Management information
Registered date
2009 Year 04 Month 07 Day
Last modified on
2016 Year 10 Month 12 Day

Link to view the page

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name

Contact us.